Shield Therapeutics plc (LON:STX – Get Free Report) shares shot up 9.4% during trading on Wednesday . The stock traded as high as GBX 4.18 ($0.06) and last traded at GBX 3.94 ($0.05). 3,379,912 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 4,994,842 shares. The stock had previously closed at GBX 3.60 ($0.05).
Shield Therapeutics Stock Up 2.6 %
The stock has a market cap of £38.13 million, a P/E ratio of -119.45 and a beta of 1.42. The firm has a 50 day simple moving average of GBX 3.59 and a two-hundred day simple moving average of GBX 2.45. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05.
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Read More
- Five stocks we like better than Shield Therapeutics
- What is MarketRank™? How to Use it
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
